We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Janssen Resubmits Xarelto sNDA, Answers Complete Response Letter
Janssen Resubmits Xarelto sNDA, Answers Complete Response Letter
September 14, 2012
Following setbacks in recent months for Janssen’s blood-clot drug Xarelto, the company has responded to an FDA complete response letter (CRL) on one sNDA for the drug and has re-submitted a separate sNDA.